Leadership Team

Mike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of

Chris joins Eagle from bluebird bio, where he served as CFO and Treasurer since 2022. He brings extensive experience in the pharmaceutical sector, having held numerous finance and treasury roles at Jubilant Pharma, Morphosys, and Pfizer.Chris began his financial career at PricewaterhouseCoopers.

Dan is our Executive Vice President of Biologics and Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure. Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a

Debra joined Eagle as part of Eagle’s 2022 acquisition of Acacia Pharma with 25 years of pharmaceutical industry experience. As Chief Commercial Officer for Acacia, Debra had responsibility for BARHEMSYS® and BYFAVO®. Prior to Acacia, Debra spent 22 years at Eli Lilly and Company in positions of

Reed joined Eagle with more than 30 years of commercial experience and 25 years of pharmaceutical leadership across multiple commercial functions. His oncology/hematology experience spans 16+ years with Novartis, Celgene, and Bristol-Myers Squibb (BMS).